Ophthalmology Biosimilars Market Estimations (2025 - 2035)

Ophthalmology Biosimilars Market Estimations (2025 - 2035)

The ophthalmology biosimilars market covers biosimilars of intravitreal anti-VEGF biologics used in eye care, including aflibercept (Eylea 2 mg) and ranibizumab (Lucentis) biosimilars, in vials and prefilled syringes, for neovascular age-related macular degeneration, diabetic macular oedema and diabetic retinopathy, macular oedema after retinal vein occlusion and myopic choroidal neovascularisation, used in retina clinics and hospitals.

📄Report ID:2522 | 📊Format: Databook | 📅Published: 19 November 2026 | ⚡Delivery: Immediate